ASH convened a multidisciplinary panel to develop evidence-based guidelines for the treatment of newly diagnosed acute myeloid leukemia in older adults, focusing on balancing treatment efficacy with ...
Panelists discuss how AML treatment has entered an exciting era of personalized medicine with increasing oral options and targeted therapies, while identifying immunotherapy as a major unmet need and ...
Although survival rates for acute myeloid leukemia (AML) continue to improve, many long-term survivors face persistent ...
Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, exceeding the 66% rate expected from VEN+AZA alone CR/CRh ...
In PV and ET, MDS risk remains lower than AML risk but increases progressively with advancing attained age. Transformation to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results